Roth Capital initiated coverage on BioRestorative Therapies with a new price target
$BRTX
Managed Health Care
Health Care
Roth Capital initiated coverage of BioRestorative Therapies with a rating of Buy and set a new price target of $37.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/1/2021 | $37.00 | Buy | Roth Capital |
Roth Capital initiated coverage of BioRestorative Therapies with a rating of Buy and set a new price target of $37.00
SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)
SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)
SC 13D/A - BioRestorative Therapies, Inc. (0001505497) (Subject)
– Blinded preliminary data demonstrate a positive trend and clear signal in Primary and Secondary endpoints – – Patient reported efficacy outcomes show a material decrease in pain and increase in function – – If positive trends continue, Company confident that the Phase 2 trial will meet its Primary and Secondary end points - – The blinded preliminary BRTX-100 data to be described in a podium presentation this morning at the ORS PSRS 7th International Spine Research Symposium – – Webcasted conference call also scheduled for today at 4:30pm EST – MELVILLE, N.Y., Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a
MELVILLE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the third quarter ended September 30, 2024 and provided an update on its business. "We have continued to execute well across all areas of our business and are looking forward to continuing to update investors on our progress as we close out the remainder of 2024," said Lance Alstodt, BioRestorative's Chief Executive Officer. "From an operating perspective, we are thrilled with our third quarter results, as we are seeing initial pro
– New blinded preliminary safety and efficacy data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in podium presentation on November 13, 2024 – – Data will be on a significantly higher number of study subjects over a longer period of time than has been presented previously -– – Company will also release its third quarter 2024 financial results and provide a business update on November 12, 2024 – – Webcasted conference call to review both the BRTX-100 data and Q3-2024 financial results scheduled for November 13th at 4:30pm EST – MELVILLE, N.Y., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX)
MELVILLE, N.Y., Jan. 11, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company" or "BioRestorative") (NASDAQ:BRTX), a life sciences company focused on stem cell-based therapies, today announced that Robert Paccasassi has been appointed Vice President of Quality Assurance/Regulatory Compliance. Mr. Paccasassi will lead quality initiatives through the next phase of the Company's growth as patient enrollment is initiated for the Phase 2 clinical trial to treat chronic lumbar disc disease. Mr. Paccasassi has over 25 years of biotech operations and combined experience in Quality Assurance, Regulatory Compliance, and Manufacturing. Prior to joining BioRestorative, Mr. Paccasassi
MELVILLE, N.Y., Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the "Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced that it has appointed Robert Kristal to the position of Chief Financial Officer. Mr. Kristal brings an extensive array of strategic and financial markets experience to the Company, including a background in advising global public life sciences companies in corporate finance, operations management systems, and strategic collaborations. Mr. Kristal is an experienced and versatile Wall Street and Bay St. professional who has built teams in both institutional sales and equity research at firms which
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)
S-8 - BioRestorative Therapies, Inc. (0001505497) (Filer)
10-Q - BioRestorative Therapies, Inc. (0001505497) (Filer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
4 - BioRestorative Therapies, Inc. (0001505497) (Issuer)
BioRestorative Therapies, Inc. (NASDAQ:BRTX) shares are trading higher Monday after the company announced it has received notice from the Nasdaq Stock Market that it has regained compliance with listing requirements. The Details: BioRestorative Therapies reported a net loss for the first quarter of $2.2 million, or 33 cents per share, compared to a net loss of $7.2 million, or $1.93 per share, from the same period last year. The company reported a loss from operations of $4.1 million, a 29% improvement from the $5.8 million loss from operations for the comparable period of 2023. The company also reported it ended the first quarter with cash, cash equivalents, and investments held
– Blinded preliminary data demonstrate a positive trend and clear signal in Primary and Secondary endpoints – – Patient reported efficacy outcomes show a material decrease in pain and increase in function – – If positive trends continue, Company confident that the Phase 2 trial will meet its Primary and Secondary end points - – The blinded preliminary BRTX-100 data to be described in a podium presentation this morning at the ORS PSRS 7th International Spine Research Symposium – – Webcasted conference call also scheduled for today at 4:30pm EST – MELVILLE, N.Y., Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a
MELVILLE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the third quarter ended September 30, 2024 and provided an update on its business. "We have continued to execute well across all areas of our business and are looking forward to continuing to update investors on our progress as we close out the remainder of 2024," said Lance Alstodt, BioRestorative's Chief Executive Officer. "From an operating perspective, we are thrilled with our third quarter results, as we are seeing initial pro
– New blinded preliminary safety and efficacy data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in podium presentation on November 13, 2024 – – Data will be on a significantly higher number of study subjects over a longer period of time than has been presented previously -– – Company will also release its third quarter 2024 financial results and provide a business update on November 12, 2024 – – Webcasted conference call to review both the BRTX-100 data and Q3-2024 financial results scheduled for November 13th at 4:30pm EST – MELVILLE, N.Y., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX)